Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Some people refer to these as the Wegovy pill but they are the same product
This portfolio reflects Lillys strategy of pursuing multiple complementary approaches to metabolic disease: Tirzepatide : Dual GIP/GLP-1 agonist (approved, injectable) Retatrutide : Triple GIP/GLP-1/glucagon agonist (Phase 3, injectable) Orforglipron : Oral GLP-1R agonist (Phase 3, oral) If retatrutide is approved, it could be positioned as a more potent option for patients requiring greater weight loss or those with MASLD, while tirzepatide and orforglipron serve other patient segments
Comparative analysis of different methods of ischemia/reperfusion in hyperglycemic stroke outcomes: interaction with tPA
Find articles by Baquero, A
